Obsessive-compulsive disorder (OCD) is a chronic condition affecting 1 in 40 adults and 1 in 100 children in the United States. This disorder is characterized by intrusive, repetitive thoughts and behaviors. Interfering with work, interpersonal relationships, and in general, patients’ enjoyment of life, OCD can have a devastating effect due to its debilitating nature. The only FDA approved treatment for OCD are serotonin reuptake inhibitors (SRIs), but the effects of these are limited. Meaningful improvement can take up to 6 to 10 weeks and symptom relief is limited. To find a better way to treat this disorder, researchers at Columbia University conducted a study involving ketamine infusions.